Global X Autonomous & Electric Vehicles vs Twist Bioscience Corp — how do they compare? Global X Autonomous & Electric Vehicles trades at $35.81, while Twist Bioscience Corp trades at $124.52 (market cap $7.72B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, Global X Autonomous & Electric Vehicles nearer its low. Which is the better fit depends on your goals.
| DRIV | TWST | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $42.53 | $124.88 |
52-Week Low | $25.23 | $24.16 |
Market Cap | — | $7.72B |
Enterprise Value | — | $7.65B |
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $36.14, up 1.6% today, with technical indicators showing a bullish trend supported by moving averages, though RSI suggests potential overbought conditions. The stock's support and resistance levels are tightly clustered around $35-$36. Recent news highlights strong global EV sales growth, particularly in Europe and China, driven by rising fuel prices and supportive policies, which may benefit DRIV's sector exposure.
The outlook for DRIV is positive due to favorable industry trends, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed, with technical strength offset by valuation concerns. Investors should weigh growth potential against execution risks in the evolving EV market.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Trailing returns across standard periods
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →